Eric Siemers Sells 10,859 Shares of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Stock

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) insider Eric Siemers sold 10,859 shares of the business’s stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $1.85, for a total value of $20,089.15. Following the completion of the sale, the insider now directly owns 106,717 shares of the company’s stock, valued at approximately $197,426.45. This trade represents a 9.24 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website.

Acumen Pharmaceuticals Price Performance

ABOS stock opened at $1.70 on Thursday. The company has a current ratio of 10.43, a quick ratio of 10.43 and a debt-to-equity ratio of 0.14. The firm’s 50-day moving average price is $2.25 and its two-hundred day moving average price is $2.51. The stock has a market capitalization of $102.14 million, a price-to-earnings ratio of -1.23 and a beta of 0.02. Acumen Pharmaceuticals, Inc. has a 12-month low of $1.69 and a 12-month high of $5.09.

Acumen Pharmaceuticals (NASDAQ:ABOS) last released its quarterly earnings results on Tuesday, November 12th. The company reported ($0.50) EPS for the quarter, missing analysts’ consensus estimates of ($0.36) by ($0.14). During the same quarter last year, the company earned ($0.24) earnings per share. As a group, equities analysts predict that Acumen Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Institutional Trading of Acumen Pharmaceuticals

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. SG Americas Securities LLC purchased a new position in Acumen Pharmaceuticals during the 3rd quarter valued at $44,000. American Century Companies Inc. increased its position in shares of Acumen Pharmaceuticals by 31.3% during the second quarter. American Century Companies Inc. now owns 45,444 shares of the company’s stock valued at $110,000 after buying an additional 10,840 shares during the period. Rhumbline Advisers bought a new position in Acumen Pharmaceuticals in the second quarter worth about $127,000. Murchinson Ltd. purchased a new stake in Acumen Pharmaceuticals in the second quarter worth about $136,000. Finally, Barclays PLC boosted its position in Acumen Pharmaceuticals by 189.1% during the 3rd quarter. Barclays PLC now owns 61,997 shares of the company’s stock valued at $154,000 after acquiring an additional 40,551 shares in the last quarter. Hedge funds and other institutional investors own 71.01% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating and issued a $15.00 price objective on shares of Acumen Pharmaceuticals in a research report on Wednesday, November 13th.

Acumen Pharmaceuticals Company Profile

Acumen Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, develops targeted therapies for the treatment of Alzheimer’s disease. The company focuses on advancing a targeted immunotherapy drug candidate sabirnetug (ACU193), a recombinant humanized immunoglobulin gamma 2 that completed Phase I clinical trial to target soluble amyloid-beta oligomers.